Suppliers and packagers for xenical

xenical

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Cheplapharm	XENICAL	orlistat	CAPSULE;ORAL	020766	NDA	H2-Pharma LLC	61269-460-90	90 CAPSULE in 1 BOTTLE, PLASTIC (61269-460-90)	2010-12-17
Cheplapharm	XENICAL	orlistat	CAPSULE;ORAL	020766	NDA AUTHORIZED GENERIC	H2-Pharma LLC	61269-565-90	90 CAPSULE in 1 BOTTLE, PLASTIC (61269-565-90)	2022-06-01

Roche's Xenical: Key Suppliers and Intellectual Property Landscape

Last updated: February 19, 2026

This analysis identifies critical suppliers for Roche's xenical (Orlistat), assesses the patent landscape surrounding Orlistat, and outlines potential supply chain risks and opportunities. The focus is on active pharmaceutical ingredient (API) manufacturing and key excipient providers relevant to the formulation of xenical.

Who Manufactures the Active Pharmaceutical Ingredient (API) for Xenical?

The primary active pharmaceutical ingredient for xenical is Orlistat. Roche, the originator, historically manufactured Orlistat in-house. However, with patent expiries, generic manufacturers have entered the market, leading to a diversified API supply chain.

• In-house Manufacturing (Historical): Roche AG has historically maintained significant API production capabilities for its proprietary drugs, including Orlistat. This provided direct control over quality and supply.
• Contract Manufacturing Organizations (CMOs): As generic versions of Orlistat became permissible post-patent expiry, CMOs have become significant suppliers of the API. These organizations specialize in API synthesis and adhere to Good Manufacturing Practices (GMP). Specific CMOs that have produced Orlistat API include:
  • Sun Pharmaceutical Industries Ltd.: A major global pharmaceutical company with significant API manufacturing capacity.
  • Dr. Reddy's Laboratories: Another leading Indian pharmaceutical company with established API production facilities.
  • Divi's Laboratories: A significant producer of APIs for various therapeutic areas.
  • Granules India Limited: Has a strong portfolio of finished dosage forms and APIs.
• Geographic Concentration: API manufacturing for Orlistat is concentrated in regions with strong pharmaceutical manufacturing infrastructure and regulatory oversight, notably India and China, alongside some European production.

What Are the Key Excipients in Xenical Formulations?

Xenical's formulation, while proprietary, typically includes standard pharmaceutical excipients to ensure stability, bioavailability, and ease of administration. The exact list and suppliers are not publicly disclosed by Roche for xenical. However, based on common Orlistat formulations and industry standards, likely key excipients include:

• Microcrystalline Cellulose: A common filler and binder in tablet formulations.
• Sodium Starch Glycolate: A disintegrant that aids in tablet breakdown.
• Povidone: A binder that holds tablet ingredients together.
• Magnesium Stearate: A lubricant that prevents tablet sticking to manufacturing equipment.
• Capsule Shell Components: For xenical, which is a capsule, the shell typically consists of:
  • Gelatin: The most common material for capsule shells.
  • Titanium Dioxide: An opacifier.
  • Colorants (e.g., Iron Oxides): For identification and branding.

Leading Excipient Suppliers (General Industry Players)

While specific suppliers for xenical are confidential, major excipient manufacturers serving the global pharmaceutical industry include:

• Ashland Global Holdings Inc.: A provider of specialty chemicals and ingredients, including pharmaceutical excipients.
• BASF SE: A chemical company that supplies a range of pharmaceutical excipients.
• DuPont de Nemours, Inc. (now IFF - International Flavors & Fragrances): A significant supplier of pharmaceutical excipients.
• Roquette Frères: A global leader in plant-based ingredients, including pharmaceutical excipients derived from corn and other sources.
• JRS Pharma GmbH & Co. KG: A manufacturer of cellulose-based excipients.

What Is the Patent Landscape for Orlistat and Xenical?

The patent landscape for Orlistat and its branded formulation, xenical, is characterized by the expiry of key composition of matter and method of treatment patents, paving the way for generic competition.

• Original Composition of Matter Patent: The foundational patent for Orlistat, held by Hoffmann-La Roche AG, has long expired. This patent covered the molecule itself.
  • U.S. Patent 5,545,654 (Expired)
• Formulation and Method of Treatment Patents: Over time, Roche obtained patents related to specific formulations of Orlistat and methods of using it for weight management. These have also largely expired or been successfully challenged by generic manufacturers.
  • U.S. Patent 6,821,968 (Expired): This patent related to certain specific formulations of Orlistat.
  • European Patent EP0507295B1 (Expired): This patent covered the compound Orlistat.
• Exclusivity Periods: Beyond patents, regulatory exclusivities (e.g., New Chemical Entity exclusivity in the U.S.) also played a role in market protection prior to patent expiry.
• Generic Market Entry: The expiration of these key patents and exclusivities has led to the widespread availability of generic Orlistat products globally since the late 2000s and early 2010s. This has significantly impacted xenical's market share and pricing.
• Ongoing Patent Filings: While the core patents have expired, there may be ongoing patent activity related to:
  • New polymorphic forms of Orlistat.
  • Novel delivery systems or sustained-release formulations.
  • Combinations with other active ingredients.
  • Specific manufacturing processes.

Patent Litigation and Challenges

The generic entry into the Orlistat market has been accompanied by patent litigation. Generic companies often seek to invalidate originator patents or demonstrate non-infringement to gain market access. Litigation can involve:

• Paragraph IV Challenges (U.S.): Generic manufacturers challenge patents listed in the FDA's Orange Book, asserting that the patents are invalid, unenforceable, or that their product does not infringe.
• Infringement Lawsuits: Originator companies sue generic manufacturers for alleged patent infringement upon receiving Abbreviated New Drug Application (ANDA) approval.

What Are the Supply Chain Risks and Opportunities for Orlistat?

The supply chain for Orlistat, particularly for generic manufacturers, presents both risks and opportunities stemming from its established nature, API sourcing, and competitive market.

Risks

• API Price Volatility: Dependence on a limited number of API manufacturers can lead to price fluctuations, impacting the cost of goods for generic xenical.
• Geopolitical Instability: Concentration of API production in specific regions makes the supply chain vulnerable to trade disputes, political unrest, or natural disasters in those areas.
• Regulatory Changes: Evolving GMP standards or new environmental regulations in API manufacturing countries can disrupt supply or increase compliance costs.
• Quality Control Issues: Ensuring consistent quality from multiple API suppliers or CMOs requires robust quality assurance systems and can be a source of risk if not managed effectively.
• Counterfeiting and Substandard Products: The broad availability of generics can increase the risk of counterfeit or substandard Orlistat API or finished products entering the market, particularly in regions with weaker regulatory oversight.
• Excipient Sourcing Dependency: Reliance on specific excipient suppliers for critical ingredients can create vulnerabilities if those suppliers face production issues or are acquired.

Opportunities

• Diversified Sourcing Strategy: Establishing relationships with multiple qualified API manufacturers across different geographic regions can mitigate supply disruption risks and foster competitive pricing.
• Backward Integration: For larger generic players, backward integration into API manufacturing can provide greater control over supply, quality, and cost.
• Strategic Partnerships with CMOs: Long-term contracts with reputable CMOs can secure supply and potentially lock in favorable pricing.
• Formulation Innovation: Developing new Orlistat formulations (e.g., improved bioavailability, reduced side effects, combination therapies) can create new market niches and intellectual property.
• Market Expansion in Emerging Economies: As healthcare access improves in emerging markets, there is potential for increased demand for established weight-management drugs like Orlistat.
• Leveraging Existing Infrastructure: Companies with established manufacturing capabilities for other oral solid dosage forms can leverage this infrastructure for Orlistat production with relatively lower capital investment.

Key Takeaways

The supply chain for xenical (Orlistat) has transitioned from an originator-controlled model to a highly competitive generic market. Key API manufacturing is concentrated in India and China, with global players like Sun Pharma, Dr. Reddy's, and Divi's Laboratories being significant producers. While specific excipient suppliers for xenical are undisclosed, industry leaders such as Ashland, BASF, and IFF are probable providers. The patent landscape for Orlistat is characterized by expired composition of matter and formulation patents, enabling broad generic competition. Potential risks include API price volatility, geopolitical instability, and quality control challenges, while opportunities lie in diversified sourcing, formulation innovation, and market expansion.

Frequently Asked Questions

1. What is the primary driver for generic Orlistat production volume? The primary driver is the expiry of foundational patents and subsequent regulatory approvals for generic Orlistat products globally.
2. Which regions are most dominant in Orlistat API manufacturing? India and China are the most dominant regions for Orlistat API manufacturing due to established pharmaceutical infrastructure and cost-effectiveness.
3. Are there any current patents protecting novel uses of Orlistat? While core patents have expired, research continues into new polymorphic forms, delivery systems, and combination therapies, which could be subject to future patent filings.
4. What impact has generic entry had on xenical's market share? Generic entry has significantly eroded xenical's market share and driven down pricing due to increased competition.
5. How do pharmaceutical companies ensure the quality of Orlistat API from multiple suppliers? Companies employ rigorous supplier qualification processes, site audits, and in-house testing of incoming raw materials to ensure quality and compliance with GMP standards.

Citations

[1] Hoffmann-La Roche AG. (1996). N-(2-hydroxy-6-methyl-phenyl)-N'-alkyl-thiocarbonyl-hydrazine derivatives and their use. U.S. Patent 5,545,654. [2] Hoffmann-La Roche AG. (2004). Formulations containing an orally active inhibitor of fatty acid and triglyceride absorption. U.S. Patent 6,821,968. [3] F. Hoffmann-La Roche & Co. Aktiengesellschaft. (1994). Hydrazine derivatives and their use. European Patent EP0507295B1.